Keywords: Gilead Sciences, Cicletanine, PAH, Ph II, Discontinued

Gilead abandons development of PAH drug cicletanine

Article | 23 August 2012

Print This

US biotech firm Gilead Sciences (Nasdaq: GILD), the world leader in HIV/AIDS drugs, has discontinued development of cicletanine, a ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in